Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Pasithea Therapeutics Corp KTTA
$0.46
▲ +3.58%
(+$0.02)
🗓️ Earnings Next Week
Open
$0.45
Prev Close
$0.44
Day Range
$0.43 – $0.47
52W Range
$0.28 – $2.06
Market Cap
$15.37M
Beta
0.27
EPS (TTM)
$-1.98
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-08-13 |
| Shares Out. | 33,410,000 |
| Website | pasithea.com/ ↗ |
| Phone | 13022880670 |
| Employees | 5 |
| Net Income | -$2.9M |
| Total Assets | $56.4M |
| Total Liabilities | $1.5M |
| Equity | $54.8M |
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Pasithea Therapeutics Corp is a publicly traded company under the ticker symbol KTTA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)